Sign In
Buy EDTXF
$0.99
-0.0010 (-0.101%)
At Close: Jul 31, 2026
Spectral Medical Provides June Tigris Trial Update
07:30am, Tuesday, 02'nd Jul 2024
TORONTO, July 02, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic
Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders
04:18pm, Friday, 07'th Jun 2024
TORONTO, June 07, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock,
Spectral Medical Inc. Announces Closing of Approximately C$8.5 Million Convertible Notes Financing
11:00am, Thursday, 30'th May 2024
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF
Spectral Medical Announces First Quarter Results and Provides Corporate Update
07:30am, Monday, 13'th May 2024
Tigris Trial Enrollment Reaches 106 Patients Bought Deal Financing Expected to Fund Completion of Tigris Trial Enrollment TORONTO, May 13, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral�
Spectral Medical Inc. Announces C$8.5 Million Bought Deal Convertible Note Financing
02:34pm, Thursday, 09'th May 2024
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF
Spectral Medical Provides April Tigris Trial Update
07:30am, Monday, 06'th May 2024
• 105 patients enrolled • April represents a record breaking month for patient enrollment TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Compan
Spectral Medical Provides Tigris Trial Update
07:00am, Wednesday, 10'th Apr 2024
TORONTO, April 10, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic
Spectral Medical Announces Fourth Quarter and Fiscal 2023 Results and Provides Corporate Update
04:00pm, Thursday, 28'th Mar 2024
TORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic
Spectral Medical Provides February Tigris Trial Update
07:30am, Wednesday, 28'th Feb 2024
TORONTO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic
Spectral Medical Provides Early February Tigris Trial Update
07:30am, Monday, 05'th Feb 2024
TORONTO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic
Spectral Medical Announces Second Quarter Results and Provides Corporate Update
08:00am, Thursday, 10'th Aug 2023
TORONTO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic
Spectral Announces Third Quarter Results
04:00pm, Wednesday, 11'th Nov 2020
Dialco's DIMI receives FDA 510(k) clearance for use in hospital and clinical settings – a significant step in the full regulatory development of DIMI
